Navigation Links
New RNAi tools enable systematic studies of gene function

An international public-private research team led by scientists at the Broad Institute of MIT and Harvard announced today the construction and availability of an extensive library of molecular reagents to silence most human and mouse genes.

As described in the March 24 issue of Cell, this library consists of small RNA molecules that can switch off genes individually, allowing the user to dissect the genetic underpinnings of normal biology and disease. These RNA-interference (RNAi)-based gene inhibitors are packaged in lentiviruses, enabling their use in virtually all types of human and mouse cells. This work springs from the RNAi Consortium (TRC), a unique collaboration among academic research institutions and leading life science companies with the mission to build comprehensive RNAi libraries and make them available to scientists worldwide.

"Switching off a single gene through RNAi reveals how that gene functions in a particular biological process. When RNAi's potential is applied to thousands of genes ?as it has been in fruit flies and nematodes ?it can provide a more complete picture of that process," said David Root, a senior author of the Cell paper and the director of TRC and the RNAi platform at the Broad Institute. "Thanks to this unique public-private effort, we now have new tools to enable the entire research community to realize the potential of RNAi in the two most important species in biomedicine."

"The RNAi library developed by TRC is a rich resource for biological discovery," said Nir Hacohen, assistant professor at Massachusetts General Hospital and Harvard Medical School, associate member of the Broad Institute and a senior author. "Ongoing studies in my own laboratory to understand how the immune system senses pathogens and appropriately targets its response will be accelerated using these tools."

RNAi gives scientists the ability to turn off an individual gene. Its workhorses are small RNA molecules, each of which i s tailored to match a fragment of a gene's unique DNA. This RNA can then bind to its gene target, rendering it inactive. In order to get the small RNAs into cells, TRC scientists packaged them in lentiviruses. "Across the spectrum of biomedicine, there is a need for tools that can be applied to diverse cell types. This is particularly true in cancer research," said Bill Hahn, assistant professor at Dana-Farber Cancer Institute and Harvard Medical School, associate member of the Broad Institute and a senior author of the study. "For TRC's library, lentiviral delivery is an especially effective means to meet this need."

The parallel analysis of thousands of genes using RNAi allows researchers to more readily pinpoint the genes that control a biological process. Therefore, TRC developed the high-throughput techniques and quality-control measures required for such genome-scale studies. "It is a distinct challenge to achieve consistent and cost-effective RNAi methods and we placed a strong emphasis on this part of the process," said David Sabatini, member of Whitehead Institute for Biomedical Research, assistant professor at Massachusetts Institute of Technology, associate member of the Broad Institute and a senior author. "In the quest to develop comprehensive tools for gene discovery in mice and humans, this technology will be a key piece in the puzzle."

To evaluate the RNAi library's performance, the scientists sampled a subset that targets approximately 1,000 human genes. They systematically inactivated these genes in a human cancer cell line to identify ones that regulate cell division during malignancy. Automated cellular imaging was used to efficiently identify dividing cells in thousands of samples. This approach uncovered more than 100 previously unknown growth regulators in addition to several known players, confirming the library's sensitivity as a vehicle for gene discovery.

"This critical new tool illustrates the requirement for acad emic and industry partnerships to drive scientific innovation," said Eric Lander, director of the Broad Institute and a senior author. "The importance of putting these reagents in the public domain will be demonstrated by the many important biomedical discoveries that will stem from them."


'"/>

Source:Broad Institute of MIT and Harvard


Related biology news :

1. Improved statistical tools reveal many linked loci
2. Virginia Tech group adds tools to DNA-targeted anti-cancer drugs
3. New tools used to control foodborne hepatitis A outbreaks related to green onions
4. MWG Biotech expands siMAX?siRNA portfolio with new scales, lengths and design tools
5. Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer
6. Discovery of new molecular tools for biosynthesis could lead to advances in use of pectin
7. Recycled paper and compost could both be key tools to control plant disease
8. Nanotech tools yield DNA transcription breakthrough
9. Molecular tools make the cut
10. Chimpanzees found to use tools to hunt mammalian prey
11. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/31/2017)... Mass. , Jan. 31, 2017  Spero ... novel therapies for the treatment of bacterial infections, ... set of antibacterial candidates from Pro Bono Bio ... increased prevalence of multi-drug resistant forms of Gram-negative ... Cantab Anti Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... and SAN FRANCISCO , Feb. ... regenerative medicine company, and Beyond Type 1, a not-for-profit ... 1 diabetes, today announced a grant from Beyond Type ... cure for type 1 and other insulin-requiring diabetes.  ... been developing innovative stem cell-derived cell replacement therapies with ...
(Date:2/22/2017)...  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Biocom Global Life Science Partnering Conference.  The presentation will ... the Torrey Pines Lodge, in San Diego.  ... who have chosen our company, amongst numerous others, to ... and clinical researchers," said Mr. Chen. "In contrast to ...
(Date:2/22/2017)... ... February 22, 2017 , ... LabRoots , the leading provider of educational ... is pleased to announce the launch of a new scholarship for young scientists seeking ... This merit-based scholarship is open to all high school seniors, 17 years or older; ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... the addition of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, ... Pennside. , Perkins joins Pennside after more than a decade with leading ...
Breaking Biology Technology: